Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jul 30;121(31):e2407546121.
doi: 10.1073/pnas.2407546121. Epub 2024 Jul 23.

Early metformin treatment: An effective approach for targeting fragile X syndrome pathophysiology

Affiliations

Early metformin treatment: An effective approach for targeting fragile X syndrome pathophysiology

Jung-Hyun Choi et al. Proc Natl Acad Sci U S A. .

Abstract

Fragile X syndrome (FXS) is the most common genetic cause of autism spectrum disorder engendered by transcriptional silencing of the fragile X messenger ribonucleoprotein 1 (FMR1) gene. Given the early onset of behavioral and molecular changes, it is imperative to know the optimal timing for therapeutic intervention. Case reports documented benefits of metformin treatment in FXS children between 2 and 14 y old. In this study, we administered metformin from birth to Fmr1-/y mice which corrected up-regulated mitogen-2 activated protein kinase/extracellular signal-regulated kinase and mammalian/mechanistic target of rapamycin complex 1 signaling pathways and specific synaptic mRNA-binding targets of FMRP. Metformin rescued increased number of calls in ultrasonic vocalization and repetitive behavior in Fmr1-/y mice. Our findings demonstrate that in mice, early-in-life metformin intervention is effective in treating FXS pathophysiology.

Keywords: Fmr1 KO mouse model; autism spectrum disorder; fragile X syndrome; mTORC1 and ERK signaling pathways; metformin.

PubMed Disclaimer

Conflict of interest statement

Competing interests statement:The authors declare no competing interest.

Figures

Fig. 1.
Fig. 1.
Metformin from birth reduced up-regulated ERK and mTORC1 signaling. Representative immunoblots from vehicle and metformin-treated WT and Fmr1−/y mice of phosphorylated and total levels of MEK (A and B), ERK (C and D), eIF4E (E and F), MMP-9 (G and H) and S6 (I and J) in HIP and PFC. Representative immunoblots from vehicle and metformin-treated WT and Fmr1−/y mice of phosphorylated and total levels of ERK (K) and S6 (L) in the striatum. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as loading control.
Fig. 2.
Fig. 2.
Correction of synaptic FMRP-binding target levels and behavioral deficits. Representative immunoblots of MAP2 (A), eEF2 (B), PUM2 (C), and synapsin (D) in HIP of vehicle and metformin-treated WT and Fmr1−/y mice. USV was measured as number of calls per minute (E) and call length (F). Repetitive behavior was assessed by measuring the time spent grooming (G) and the number of grooming bouts (H).

References

    1. Hagerman R. J., et al. , Fragile X syndrome. Nat. Rev. Dis. Primers 3, 17065 (2017). - PubMed
    1. Hoeffer C. A., et al. , Altered mTOR signaling and enhanced CYFIP2 expression levels in subjects with fragile X syndrome. Genes Brain Behav. 11, 332–341 (2012). - PMC - PubMed
    1. Gantois I., et al. , Metformin ameliorates core deficits in a mouse model of fragile X syndrome. Nat. Med. 23, 674–677 (2017). - PubMed
    1. Biag H. M. B., et al. , Metformin treatment in young children with fragile X syndrome. Mol. Genet. Genomic Med. 7, e956 (2019). - PMC - PubMed
    1. Dy A. B. C., et al. , Metformin as targeted treatment in fragile X syndrome. Clin. Genet. 93, 216–222 (2018). - PMC - PubMed

MeSH terms

Substances